General
Preferred name
Anlotinib
Synonyms
AL3818 dihydrochloride ()
APCII ()
ATCII ()
FU KE WEI ()
ALTN ()
APC I ()
ATC I ()
AL3818 ()
Anlotinib Dihydrochloride ()
AL 3818 ()
AL-3818 ()
catequentinib ()
Anlotinib (AL3818) dihydrochloride ()
Catequentinib dihydrochloride ()
Anlotinib hydrochloride ()
CATEQUENTINIB HYDROCHLORIDE ()
Anlotinib (hydrochloride) ()
P&D ID
PD056639
CAS
1058156-90-3
1360460-82-7
1058157-76-8
Tags
available
drug
drug candidate
Drug indication
Cervical cancer
Peritoneal cavity cancer
Alveolar soft part sarcoma
Fallopian tube cancer
Ovarian cancer
Synovial sarcoma
Endometrial cancer
Leiomyosarcoma
Drug Status
investigational
approved
Max Phase
3.0
1.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Catequentinib (AL3818; anlotinib in China) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (VEGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123 .
Note that anlotinib appears to be a 'pseudo' INN, that uses the -tinib INN stem for tyrosine kinase inhibitors, but has not been submitted to the World Health Organisation for ratification, and in fact a genuine INN request for 'catequentinib' was submitted for this chemical structure to the WHO (in Proposed List 121) and this became the recommended INN in April 2020.. (GtoPdb)
Note that anlotinib appears to be a 'pseudo' INN, that uses the -tinib INN stem for tyrosine kinase inhibitors, but has not been submitted to the World Health Organisation for ratification, and in fact a genuine INN request for 'catequentinib' was submitted for this chemical structure to the WHO (in Proposed List 121) and this became the recommended INN in April 2020.. (GtoPdb)
DESCRIPTION
Anlotinib (AL3818) is a non-selective inhibitor of multiple receptor tyrosine kinases, including vascular endothelial growth factor receptor type 2 (VEGFR-2, FLT1) and type 3 (VEGFR-3, FLT4). It is being investigated for antineoplastic and anti-angiogenic potential. The dihydrochloride has PubChem CID: 57380530. Preparation and crystallisation of AL3818 is described in patent WO2016179123.
(PKIDB)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
10
AdooQ Bioactive Compound Library
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugMAP
Guide to Pharmacology
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
36
Molecular Weight
407.16
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
2
Rotatable Bonds
6
Ring Count
5
Aromatic Ring Count
4
cLogP
4.83
TPSA
82.39
Fraction CSP3
0.26
Chiral centers
0.0
Largest ring
6.0
QED
0.48
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
KDR, PDGFRB
KDR
FLT4
VEGFR
MOA
PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor
Source data
